Advertisement

Treatment of Resistant Hodgkin’s Lymphoma with Bone Marrow Transplantation in Italy

  • A. M. Carella
  • A. M. Marmont
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 117)

Abstract

High-dose chemotherapy and autologous or allogeneic bone marrow transplantation are known to be useful in patients with hematological malignancies. The encouraging results of this approach in the treatment of acute leukemias prompted us to investigate its use in patients with Hodgkin’s lymphoma not being cured by primary conventional chemotherapy.

Keywords

Bone Marrow Transplantation Allogeneic Bone Marrow Bone Marrow Transplantation Unit Generalize Herpes Simplex Initial Complete Remission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carella AM, Congiu A, Santini G et al. (1986) High dose chemotherapy (HDC) and autologous bone marrow transplantation in advanced highly treated Hodgkin’s disease (AHTHD). Bone Marrow Transplant 1: 293–296Google Scholar
  2. Carella AM, Congiu A, Santini G et al. (1987) High-dose cyclophosphamide, etoposide and BCNU with autologous BMT (ABMT) rescue in advanced resistant Hodgkin’s disease patients. Bone Marrow Transplant 2 [Suppl 1]: 210Google Scholar
  3. Carella AM, Congiu A, Mazza P et al. (1988) High-dose chemotherapy with autologous BMT “rescue” in 50 advanced resistant Hodgkin’s disease patients. An Italian Study Group Report. J Clin Oncol 6 [Suppl 9]: 1411–1416PubMedGoogle Scholar
  4. Jagannath S, Dicke KA, Armitage JO, Cabanillas F, Horwitz U, Vellekoop L, Zander AR, Spitzer G (1986) High dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med 102: 163–168Google Scholar
  5. Santoro A, Bonfante V, Bonadonna G et al. (1982) Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease. Ann Intern Med 96: 139–143PubMedGoogle Scholar
  6. Santoro A, Viviani S, Valagussa P et al. (1986) CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin’s disease. Semin Oncol 13 [Suppl 1]: 23–26PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • A. M. Carella
    • 1
  • A. M. Marmont
    • 1
  1. 1.Department of HematologyBone Marrow Transplantation UnitGenovaItaly

Personalised recommendations